Another study indicated that YTHDF2 expression was positively associated with higher malignant grade, a molecular subtype of glioma, and poorer prognosis, and accelerated UBXN1 mRNA degradation via METTL3-mediated m6A [61]; this in turn promoted NF-κB activation [62]. The gene discussed is METTL3; the disease is central nervous system cancer.